Two healthcare companies focused on AI-powered technologies—Densitas and MaxQ AI—have announced that they will have FDA-approved solutions available on the Nuance AI Marketplace. The marketplace is designed like an app store, giving users of Nuance’s PowerScribe reporting system access to a number of products from different vendors.
Densitas, a breast health company based out of Halifax, Nova Scotia, Canada, is making its densitas densityai breast density assessment software available. The software uses AI to produce reproducible assessments that follow the American College of Radiology’s BI-RADS grading system.
“Our presence on the Nuance AI Marketplace makes us readily accessible to over 6,500 connected healthcare facilities,” Mo Abdolell, CEO of Densitas, said in a prepared statement. “We are excited to see this unique level of workflow integration that supports improved decision making for better patient care and increased reporting efficiency.”
MaxQ AI, meanwhile, is making its ACCIPIO Ix and ACCIPIO Ax platforms available through the marketplace. Both platforms use deep learning algorithms to evaluate imaging findings and help physicians prioritize patients as needed.
“The Nuance AI Marketplace for Diagnostic Imaging brings our revolutionary AI-powered ICH detection solutions to radiologists across the globe in their preferred workflow,” Gene Saragnese, CEO of MaxQ AI, said in a separate prepared statement. “This availability of our Accipio ICH detection, stroke, and head trauma solutions through Nuance’s cloud-based marketplace will support potential diagnostic improvements, which will improve patient outcomes and lower healthcare costs.”
More information on the Nuance AI marketplace is available here.